Search results for "BES"

showing 10 items of 3692 documents

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

2007

Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant range of concentrations (0.85-27.2 microg ml(-1) paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as histopathological parameters. Progesterone receptor (PR) m…

Cancer Researchmedicine.medical_specialtyReceptor StatusPaclitaxelmedicine.medical_treatmentBreast Neoplasmsprogesterone receptorchemistry.chemical_compoundBreast cancerInternal medicineProgesterone receptormedicineHumansRNA Messengerprimary tumour cellsChemotherapyBase SequenceDose-Response Relationship Drugbusiness.industryAntineoplastic AgentsPhytogenic/therapeutic use/Base Sequence/Breast Neoplasms/Pathology/DNA Probes/Dose-Response RelationshipDrug/Drug ResistanceNeoplasm/Humans/Immunohistochemistry/Paclitaxel/RNAMessenger/genetics/ReceptorsProgesterone/physiologyindividualized chemotherapymedicine.diseaseAntineoplastic Agents PhytogenicImmunohistochemistryIn vitrochemosensitivityEndocrinologyOncologyPaclitaxelchemistryDrug Resistance NeoplasmCancer researchImmunohistochemistryTranslational TherapeuticsDNA ProbesReceptors ProgesteroneBreast carcinomabusinessBritish Journal of Cancer
researchProduct

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three res…

Cancer Researchmedicine.medical_specialtyReferralmedia_common.quotation_subjectBest practiceMEDLINEFertilitylcsh:RC254-282Cost EffectivenessFertilidade03 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeJournal ArticleQuality of CareMedicineFertility preservationmedia_commonOncofertilityEthicsMedicine(all)Response rate (survey)030219 obstetrics & reproductive medicinebusiness.industryHealth Services and OutcomesORIGINAL REPORTSlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSupportive CarePolicy AnalysisWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthFertilityOncology030220 oncology & carcinogenesisFamily medicineScale (social sciences)Quality of Life/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428business
researchProduct

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

2021

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%

Cancer Researchmedicine.medical_specialtycutaneous squamous cell carcinomaLocally advancedBest Overall Response[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyArticle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalMedicineAdverse effectGroup performanceRC254-282Immune statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensMean agemedicine.diseasechronic dermatosisToxic epidermal necrolysis3. Good healthimmunocompromisedreal-life settingOncology030220 oncology & carcinogenesisPD-1–blocking antibodycemiplimabbusiness[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment

2012

Abstract Background A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of information regarding BC prognostic factors and care in this population. The aims of this study were to assess the prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the predictive factors of treatments administered to this population. Methods A population-based study was performed using data from the Cote d’Or breast and gynaecological cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of diagnosis made between January 1998 and December 2008 were retrospectively selected.…

Cancer Researchmedicine.medical_treatmentComorbidityBreast cancerBreast-conserving surgeryRegistriesMastectomyAged 80 and overeducation.field_of_studyPredictors of treatmentRelative survivalPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyTreatment OutcomeOncologyPopulation SurveillanceHypertensionFemaleFranceMastectomyResearch Articlemedicine.medical_specialtyPopulationBreast NeoplasmsPrognostic factorsRelative survivallcsh:RC254-282Breast cancerDrug TherapyInternal medicineDiabetes MellitusmedicineAdjuvant therapyGeneticsHumansObesityElderly womeneducationSurvival analysisAgedNeoplasm StagingRetrospective StudiesGynecologyRadiotherapybusiness.industrymedicine.diseaseSurvival AnalysisLogistic ModelsMultivariate AnalysisHormone therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Expertise préalable à la création d’un tableau de maladie professionnelle ou à l’élaboration de recommandations aux comités régionaux de reconnaissan…

2022

L’amiante est classé en tant que substance cancérogène avérée pour l’humain (groupe 1 du Centre International de Recherche sur la Cancer (CIRC)) depuis les années 70 pour le poumon et la plèvre. La monographie sur l’amiante actualisée en 2012 indique que des preuves suffisantes sont maintenant disponibles pour démontrer le lien entre l’exposition à l’amiante et les cancers du larynx et de l'ovaire. Dans cette monographie, les cancers du pharynx, de l’estomac et les cancers colorectaux sont considérés comme possiblement liés à une exposition à l’amiante, mais avec un niveau de preuve limité.A ce jour, seuls les cancers broncho-pulmonaires provoqués par l'inhalation de poussières d'amiante [t…

Cancer du larynxOvary cancerCancer de l’ovaireMedical diagnosisOccupational diseaseCausal relationshipAsbestosExposition professionnelleOccupational exposureMaladie professionnelleAmianteDiagnostic médical[SDV] Life Sciences [q-bio]Laryngeal cancer[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCompensationRelation causaleReconnaissance
researchProduct

Building an advocacy model to improve the dementia-capability of health plans in California

2021

Background Given the high and growing prevalence of Alzheimer's disease and related dementias, and the intensity of this population's care needs, it is imperative that healthcare systems increase their capacity to effectively serve people living with dementia (PLwD). The Dementia Cal MediConnect (Dementia CMC) project proposes an advocacy model that may foster dementia-capable systems change. Methods The Dementia CMC project was a 5-year partnership (2013-2018) between local Alzheimer's organizations and 10 managed care health plans (HPs) in California's duals demonstration. It used an advocacy model with the following steps: (1) Identify dementia-capable best practices to set as systems ch…

Capacity BuildingSystems AnalysisReferralBest practicePopulationPatient AdvocacyPublic-Private Sector PartnershipsCaliforniaNursingAlzheimer DiseaseHumansMedicineDementiaBusiness caseeducationeducation.field_of_studyGovernmentbusiness.industrymedicine.diseaseOrganizational InnovationGeneral partnershipVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Geriatri: 778Managed careDementiasense organsGeriatrics and GerontologybusinessDelivery of Health Care
researchProduct

CONTROLLING THE FUNCTIONALIZATION OF CARBON NANOTUBES AND GRAPHENE NANOPLATELETS

2013

The functionalization of carbon nanostructures by diazonium chemistry is a versatile strategy to obtain soluble nanomaterials with degrees of functionalization among the highest ever reported.[1,2] Starting from these premises we have studied the functionalization of single, double and multi-walled carbon nanotubes and graphene nanoplatelets by addition of aryl diazonium salts generated in situ by treatment of 4-substituted anilines with isopentylnitrite. Taking advantage of highly controlled flow synthesis [3-5] and following a thorough purification and characterization protocol (UV-vis, TGA, ATR-IR, AFM and other surface tools), we have investigated the key parameters to obtain both funct…

Carbon Nanotubes Graphene
researchProduct

Carbon based nanomaterials for the detection of narrow therapeutic index pharmaceuticals

2020

Precise detection of important pharmaceuticals with narrow therapeutic index (NTI) is very critical as there is a small window between their effective dose and the doses at which the adverse reactions are very likely to appear. Regarding the fact that various pharmacokinetics will be plausible while considering pharmacogenetic factors and also differences between generic and brand name drugs, accurate detection of NTI will be more important. Current routine analytical techniques suffer from many drawbacks while using novel biosensors can bring up many advantages including fast detection, accuracy, low cost with simple and repeatable measurements. Recently the well-known carbon Nano-allotrop…

Carbon nanostructuresBrand namesNanotubes CarbonChemistrytechnology industry and agricultureBiosensing TechniquesNanostructuresAnalytical ChemistryTherapeutic IndexPharmaceutical PreparationsCarbon based nanomaterialsGraphiteBiochemical engineeringSmall windowTalanta
researchProduct

Thin-Film Heterojunction by Carbon Nanotube Derivatives with Enhanced Solubility and Optical Properties

2012

Carbon nanotubes Bulk heterojunctions Organic solar cells Photovoltaics
researchProduct

Multi-functional hybrid-carbon nanotubes for advanced Ultra-High Molecular Weight Polyethylene-based nanocomposites: a novel approach for stabilizati…

2015

Our results demonstrate that immobilizing stabilizing molecules on nanoparticles, and using the latter as multifunctional filler for nanocomposites, is a viable route towards to produce high-performance polymeric materials

Carbon nanotubes Ultra-High Molecular Weight Polyethylene nanocomposites stabilization
researchProduct